DCR:那不勒斯预后评分是转移性结直肠癌患者有用的预后评价工具

2020-03-01 不详 MedSci原创

全身性炎症可能会影响各种癌症患者对全身化学疗法的反应或预后。在那不勒斯预后评分的基础上,炎症和营养状态是一种评价接受手术的结直肠癌患者有用的预后标志;然而,其在转移性结直肠癌患者中的意义尚不清楚。因此,本项研究旨在评估那不勒斯预后评分在评价接受一线化疗的转移性结直肠癌患者中的预后意义。

背景及目的:
全身性炎症可能会影响各种癌症患者对全身化学疗法的反应或预后。在那不勒斯预后评分的基础上,炎症和营养状态是一种评价接受手术的直肠癌患者有用的预后标志;然而,其在转移性直肠癌患者中的意义尚不清楚。因此,本项研究旨在评估那不勒斯预后评分在评价接受一线化疗的转移性结直肠癌患者中的预后意义。

方法:
这是对前瞻性收集数据的回顾性研究。共有259例患者接受了转移性大肠癌一线化疗。主要观察指标:那不勒斯预后评分;单核细胞比率和中性粒细胞:淋巴细胞的比例是由白蛋白和胆固醇浓度,淋巴细胞的综合得分来计算。根据增加的那不勒斯评分将患者分为3组(0、1、2组),并评估那不勒斯预后评分与临床病理特征和总体生存率的关联。

结果:
那不勒斯较高的预后评分与右侧原发肿瘤和同步转移呈正相关,与原发肿瘤切除呈负相关。第2组(那不勒斯预后评分高)的患者的总生存期明显少于第 0和第1组(p = 0.012和0.022)。多因素Cox回归分析将那不勒斯的预后评分确定为整体生存的独立预后因素(HR = 1.574;p = 0.004)。随时间变化的受试者工作特征曲线分析表明,那不勒斯的预后评分比其他预后因素对预测整体生存期更为敏感。

结论:
那不勒斯预后评分可能是转移性结直肠癌接受全身化疗的患者有用的预后评价工具。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1386596, encodeId=42411386596f5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Mar 03 11:43:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444616, encodeId=ac381444616b3, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Mar 03 11:43:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453353, encodeId=643914533531e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Mar 03 11:43:00 CST 2020, time=2020-03-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1386596, encodeId=42411386596f5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Mar 03 11:43:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444616, encodeId=ac381444616b3, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Mar 03 11:43:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453353, encodeId=643914533531e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Mar 03 11:43:00 CST 2020, time=2020-03-03, status=1, ipAttribution=)]
    2020-03-03 huagfeg
  3. [GetPortalCommentsPageByObjectIdResponse(id=1386596, encodeId=42411386596f5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Mar 03 11:43:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444616, encodeId=ac381444616b3, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Tue Mar 03 11:43:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453353, encodeId=643914533531e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Mar 03 11:43:00 CST 2020, time=2020-03-03, status=1, ipAttribution=)]